Morgan Stanley Downgrades RxSight Inc. (RXST) to Equalweight

Morgan Stanley analyst Patrick Wood downgraded RxSight Inc. (NASDAQ: RXST) from Overweight to Equalweight with a price target of $9.00.

The analyst comments "On our new numbers, RXST is trading on 0.8x 2026 sales, leaving it as one of the cheapest stocks in the coverage universe. Regardless, it's completely unclear to us what the growth rate over the next few years should look like, and we can't recall seeing such an abrupt deceleration in a product line as this for a long time. All this means it's just impossible for us to remain Overweight on the stock, despite what could be considered a conservative guide, as visibility is just too low. Moving to Equal-weight with a PT of $9 based on 1.0x 2026e sales."

For an analyst ratings summary and ratings history on RxSight Inc. click here. For more ratings news on RxSight Inc. click here.

Shares of RxSight Inc. closed at $7.74 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results